Unknown

Dataset Information

0

Sulindac, a non-steroidal anti-inflammatory drug, mediates breast cancer inhibition as an immune modulator.


ABSTRACT: The cooperation of adaptive immunity with pharmacologic therapy influences cancer progression. Though non-steroidal anti-inflammatory drugs (NSAIDs) have a long history of cancer prevention, it is unclear whether adaptive immune system affects the action of those drugs. In present study, we revealed a novel immunological mechanism of sulindac. Our data showed that sulindac had substantial efficacy as a single agent against 4T1 murine breast cancer and prolonged the survival of tumor-bearing mice. However, in the athymic nude mice, sulindac treatment was ineffective. Further in vivo T cell subsets depletion experiments showed that CD8+ T lymphocytes deficiency reversed the anti-tumor effect of sulindac. In addition, sulindac significantly reduced M2 macrophages recruitment, cancer-related inflammation and tumor angiogenesis. Our results advance our understanding of the mechanisms of NSAIDs, and more importantly, this will provide insight into rational drug design or antitumor immunotherapy.

SUBMITTER: Yin T 

PROVIDER: S-EPMC4725989 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4661391 | biostudies-literature
| S-EPMC2966109 | biostudies-literature
| S-EPMC10489748 | biostudies-literature
| S-EPMC9847679 | biostudies-literature
| S-EPMC3076957 | biostudies-literature
| S-EPMC10612326 | biostudies-literature
| S-EPMC3754997 | biostudies-literature
| S-EPMC6730525 | biostudies-literature
| S-EPMC1130907 | biostudies-other
| S-EPMC7869531 | biostudies-literature